Henderson Jane — SEC insider filings
SEC reporting owner CIK 1422304. 37 insider filings on record with FilingPulse; latest filed 2026-10-26.
Transaction summary — filings shown
Covers all 37 filings on record, filed 2021-05-10 to 2026-10-26. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 26 legs across 15 filings — 76,500 shares, $4,691,422 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 49.
- Largest priced transaction: sale of 22,498 shares @ $54.46 ($1,225,291) in Akero Therapeutics, Inc., filed 2023-06-21.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Apogee Therapeutics, Inc. (APGE) | Chief Financial Officer | 17 | — | 23 legs · 33,500 sh · $2,382,367 | 8 |
| Akero Therapeutics, Inc. (AKRO) | Director | 8 | — | 3 legs · 43,000 sh · $2,309,056 | 16 |
| IVERIC bio, Inc. (ISEE) | Director | 5 | — | — | 17 |
| CARGO Therapeutics, Inc. (CRGX) | Director | 3 | — | — | 4 |
| Lycia Therapeutics, Inc. (LYCA) | Director | 2 | — | — | 2 |
| Adagio Therapeutics, Inc. (ADGI) | Chief Financial Officer | 1 | — | — | 1 |
| Sesen Bio, Inc. (SESN) | Director | 1 | — | — | 1 |
Insider filings — Henderson Jane
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-26 | 4 | Lycia Therapeutics, Inc. (LYCA) | Grant/award (A): 57,666 (derivative) @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-10-22 | 3 | Lycia Therapeutics, Inc. (LYCA) | Holdings only — no transactions reported | EDGAR |
| 2026-09-03 | 4 | Apogee Therapeutics, Inc. (APGE) | Disposition to issuer (D): 158,371 · Disposition to issuer (D): 175,345 (derivative) · Disposition to issuer (D): 124,962 (derivative) · Disposition to issuer (D): 83,690 (derivative) | EDGAR |
| 2026-07-24 | 4 | Apogee Therapeutics, Inc. (APGE) | Gift (G): 15,000 @ $0 | EDGAR |
| 2026-05-04 | 4 | Apogee Therapeutics, Inc. (APGE) | Sale (S): 811 @ $81.02 · Sale (S): 900 @ $82.60 · Sale (S): 289 @ $83.16 | EDGAR |
| 2026-04-17 | 4 | Apogee Therapeutics, Inc. (APGE) | Sale (S): 2,000 @ $90 | EDGAR |
| 2026-04-03 | 4 | Apogee Therapeutics, Inc. (APGE) | Sale (S): 900 @ $84.46 · Sale (S): 1,100 @ $85.46 | EDGAR |
| 2026-03-27 | 4 | Apogee Therapeutics, Inc. (APGE) | Sale (S): 2,000 @ $85 | EDGAR |
| 2026-03-04 | 4 | Apogee Therapeutics, Inc. (APGE) | Sale (S): 300 @ $68.27 · Sale (S): 300 @ $69.43 · Sale (S): 994 @ $70.45 · Sale (S): 406 @ $71.66 | EDGAR |
| 2026-02-04 | 4 | Apogee Therapeutics, Inc. (APGE) | Sale (S): 792 @ $65.21 · Sale (S): 1,108 @ $66.15 · Sale (S): 100 @ $66.89 | EDGAR |
| 2026-01-06 | 4 | Apogee Therapeutics, Inc. (APGE) | Sale (S): 1,920 @ $74.13 · Sale (S): 4,080 @ $75.20 · Sale (S): 2,000 @ $80 · Grant/award (A): 83,690 (derivative) @ $0 | EDGAR |
| 2025-12-23 | 4 | Apogee Therapeutics, Inc. (APGE) | Sale (S): 1,500 @ $80 | EDGAR |
| 2025-12-09 | 4 | Akero Therapeutics, Inc. (AKRO) | Disposition to issuer (D): 9,398 · Disposition to issuer (D): 26,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 13,000 (derivative) · Disposition to issuer (D): 13,000 (derivative) · +1 more | EDGAR |
| 2025-12-05 | 4 | Apogee Therapeutics, Inc. (APGE) | Sale (S): 1,500 @ $75 | EDGAR |
| 2025-11-28 | 4 | Apogee Therapeutics, Inc. (APGE) | Sale (S): 1,500 @ $70 | EDGAR |
| 2025-11-14 | 4 | Apogee Therapeutics, Inc. (APGE) | Sale (S): 2,000 @ $65 | EDGAR |
| 2025-11-13 | 4 | Apogee Therapeutics, Inc. (APGE) | Sale (S): 1,000 @ $60 | EDGAR |
| 2025-08-19 | 4 | CARGO Therapeutics, Inc. (CRGX) | Disposition to issuer (D): 25,000 (derivative) | EDGAR |
| 2025-08-12 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 3,000 @ $7.01 · Sale (S): 3,000 @ $47.46 · Option exercise (M): 3,000 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | CARGO Therapeutics, Inc. (CRGX) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Akero Therapeutics, Inc. (AKRO) | Grant/award (A): 9,398 @ $0 | EDGAR |
| 2024-12-11 | 4 | Apogee Therapeutics, Inc. (APGE) | Grant/award (A): 124,962 (derivative) @ $0 | EDGAR |
| 2024-08-23 | 4 | Apogee Therapeutics, Inc. (APGE) | Sale (S): 6,000 @ $48.26 | EDGAR |
| 2024-06-11 | 4 | Akero Therapeutics, Inc. (AKRO) | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | CARGO Therapeutics, Inc. (CRGX) | Grant/award (A): 19,785 (derivative) @ $0 · Grant/award (A): 39,402 (derivative) @ $0 | EDGAR |
| 2023-12-20 | 4 | Apogee Therapeutics, Inc. (APGE) | Grant/award (A): 175,345 (derivative) @ $0 | EDGAR |
| 2023-07-13 | 4 | IVERIC bio, Inc. (ISEE) | Disposition to issuer (D): 22,088 · Disposition to issuer (D): 7,500 (derivative) · Disposition to issuer (D): 32,000 (derivative) · Disposition to issuer (D): 16,000 (derivative) · Disposition to issuer (D): 16,000 (derivative) · Disposition to issuer (D): 16,000 (derivative) · +2 more | EDGAR |
| 2023-06-27 | 4 | Akero Therapeutics, Inc. (AKRO) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2023-06-21 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 40,000 @ $7.01 · Sale (S): 17,502 @ $53.79 · Sale (S): 22,498 @ $54.46 · Option exercise (M): 40,000 (derivative) @ $0 | EDGAR |
| 2023-05-19 | 4 | IVERIC bio, Inc. (ISEE) | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2023-05-15 | 4 | IVERIC bio, Inc. (ISEE) | Option exercise (M): 14,588 · Option exercise (M): 14,588 (derivative) @ $0 | EDGAR |
| 2022-06-03 | 4 | Akero Therapeutics, Inc. (AKRO) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2022-05-13 | 4 | IVERIC bio, Inc. (ISEE) | Option exercise (M): 7,500 · Option exercise (M): 7,500 (derivative) @ $0 · Grant/award (A): 14,588 (derivative) @ $0 · Grant/award (A): 23,186 (derivative) @ $0 | EDGAR |
| 2022-02-01 | 4 | Adagio Therapeutics, Inc. (ADGI) | Grant/award (A): 175,000 (derivative) @ $0 | EDGAR |
| 2021-06-03 | 4 | Akero Therapeutics, Inc. (AKRO) | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2021-05-20 | 4 | IVERIC bio, Inc. (ISEE) | Grant/award (A): 15,500 (derivative) @ $0 · Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2021-05-10 | 4 | Sesen Bio, Inc. (SESN) | Grant/award (A): 92,500 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-05-05 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1422304 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs